Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00142974
Status:
TERMINATED
Last Update Posted:
2012-04-20
First Post:
2005-08-31
Brief Title:
Assessment of the Effect of Tegaserod 2 mg Tid and 6 mg Tid on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Assessment of the Effect of Tegaserod 2 mg Tid and 6 mg Tid on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy
Status:
TERMINATED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study was terminated early in April 2005 due to low patient enrollment
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to evaluate the safety tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None